Transplant protocol for EBV-related T/NK lymphoproliferative disease
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a stronger transplant conditioning regimen to treat a rare immune disorder caused by the Epstein-Barr virus. It aims to improve outcomes and reduce a complication called graft-versus-host disease, where donor cells attack the patient's body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with a specific immune disease linked to the Epstein-Barr virus (EBV-T/NK LPD).
- You need to be 18 years old or younger.
- You must be planning to have a stem cell transplant from a donor at Beijing Children's Hospital.
- Your donor must meet certain rules based on their age, how closely related they are, or other health factors.
- You and your family must agree to the plan by signing a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests a new immune cell therapy (EBV-TCR-T cells) for people with a severe immune reaction caused by the Epstein-Barr virus (EBV-HLH) or active EBV infection. The treatment uses special cells from a matched donor to help your body fight the virus.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests a new treatment using specially prepared immune cells (called T cells) that fight the Epstein-Barr virus (EBV). It is for people who have EBV-related conditions, especially after a stem cell or organ transplant, and aims to help control the disease.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
Hear when a new EBV-T/NK LPD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.